Willis Johnson & Associates’s Pfizer PFE Stock Holding History

Willis Johnson & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,012	Closed	-$206K	–	124
2022 Q4	$206K	Buy	+4,012	New	+$192K	0.03%	109

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Willis Johnson & Associates's PFE Position: Q1 2023 in Review

Willis Johnson & Associates sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,012 shares — an estimated $206K sold.

Willis Johnson & Associates first reported a position in PFE in Q4 2022 and held it in 1 quarter. The position peaked at $206K in Q4 2022. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Willis Johnson & Associates reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Willis Johnson & Associates sold 4,012 Pfizer shares in Q1 2023, an estimated $206K.
Willis Johnson & Associates first reported a position in Pfizer in Q4 2022 and held it in 1 quarter.
Willis Johnson & Associates's Pfizer position peaked at $206K in Q4 2022.
3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Willis Johnson & Associates's 13F filing for Q1 2023, filed 6 Apr 2023.